NCT05101213View on ClinicalTrials.gov

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 6, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Adenovirus InfectionBK Virus InfectionCytomegaloviral InfectionHematopoietic and Lymphoid Cell NeoplasmJC Virus InfectionMalignant Solid NeoplasmSymptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
BIOLOGICAL

Virus-specific Cytotoxic T-lymphocytes

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER